Sulbactam-durlobactam for infections caused by Acinetobacter baumannii-calcoaceticus complex

Simone Giuliano¹, Francesco Sbrana², Carlo Tascini³

Affiliations

¹ Infectious Diseases Clinic, Udine University Hospital, Udine, Italy.
² Lipoapheresis Unit, Reference Center for Diagnosis and Treatment of Inherited Dyslipidemias, Fondazione Toscana Gabriele Monasterio, Pisa 56124, Italy. Electronic address: francesco.sbrana@ftgm.it.
³ Infectious Diseases Clinic, Udine University Hospital, Udine, Italy; Department of Medical Area, Udine University Hospital, Udine, Italy; Lipoapheresis Unit, Reference Center for Diagnosis and Treatment of Inherited Dyslipidemias, Fondazione Toscana Gabriele Monasterio, Pisa 56124, Italy.

PMID: 37442147
DOI: 10.1016/S1473-3099(23)00422-X

Comment

Sulbactam-durlobactam for infections caused by Acinetobacter baumannii-calcoaceticus complex

Simone Giuliano et al. Lancet Infect Dis. 2023 Aug.

. 2023 Aug;23(8):e274.

doi: 10.1016/S1473-3099(23)00422-X. Epub 2023 Jul 10.

Authors

Simone Giuliano¹, Francesco Sbrana², Carlo Tascini³

Affiliations

¹ Infectious Diseases Clinic, Udine University Hospital, Udine, Italy.
² Lipoapheresis Unit, Reference Center for Diagnosis and Treatment of Inherited Dyslipidemias, Fondazione Toscana Gabriele Monasterio, Pisa 56124, Italy. Electronic address: francesco.sbrana@ftgm.it.
³ Infectious Diseases Clinic, Udine University Hospital, Udine, Italy; Department of Medical Area, Udine University Hospital, Udine, Italy; Lipoapheresis Unit, Reference Center for Diagnosis and Treatment of Inherited Dyslipidemias, Fondazione Toscana Gabriele Monasterio, Pisa 56124, Italy.

PMID: 37442147
DOI: 10.1016/S1473-3099(23)00422-X

No abstract available

PubMed Disclaimer

Conflict of interest statement

CT has received funds for speaking at symposia for Pfizer, Novartis, Merck, Angelini, Thermofischer, Biomerieux, Basilea, Correvio, Zambon, Hikma, and Astellas. SG and FS declare no competing interests.

Comment in

Sulbactam-durlobactam for infections caused by Acinetobacter baumannii-calcoaceticus complex - Authors' reply.
Kaye KS, McLeod SM, O'Donnell JP, Altarac D. Kaye KS, et al. Lancet Infect Dis. 2023 Aug;23(8):e275-e276. doi: 10.1016/S1473-3099(23)00423-1. Epub 2023 Jul 10. Lancet Infect Dis. 2023. PMID: 37442148 No abstract available.

Comment on

Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).
Kaye KS, Shorr AF, Wunderink RG, Du B, Poirier GE, Rana K, Miller A, Lewis D, O'Donnell J, Chen L, Reinhart H, Srinivasan S, Isaacs R, Altarac D. Kaye KS, et al. Lancet Infect Dis. 2023 Sep;23(9):1072-1084. doi: 10.1016/S1473-3099(23)00184-6. Epub 2023 May 11. Lancet Infect Dis. 2023. PMID: 37182534 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Sulbactam-durlobactam for infections caused by Acinetobacter baumannii-calcoaceticus complex

Affiliations

Sulbactam-durlobactam for infections caused by Acinetobacter baumannii-calcoaceticus complex

Authors

Affiliations

Conflict of interest statement

Comment in

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources